BLA 761279 · Eli Lilly and CO
Omvoh
Mirikizumab-Mrkz · Subcutaneous, Single-Use · Interleukin-23 Antagonist
NovelOrphanCDER novel approval, Oct 26, 2023: To treat ulcerative colitis
Last checked: Nov 20, 2026Latest source record: Oct 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Oct 26, 2023
Approved uses
3
Original approval plus efficacy supplements
Registered trials
51
15 Phase 3, 12 recruiting
FAERS reports
903
489 serious, 26 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 16, 2026.
OMVOH is indicated for the treatment of: moderately to severely active ulcerative colitis in adults. moderately to severely active Crohn's disease in adults. OMVOH TM is an interleukin-23 antagonist indicated for the treatment of: moderately to severely active ulcerative colitis in adults ( 1 ) moderately to severely active Crohn's disease in adults ( 1 )
Mechanism: Mirikizumab-mrkz is a humanized IgG4 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor. IL-23 is involved in mucosal inflammation and affects the differentiation, expansion, and survival of T cell subsets, and innate immune cell subsets, which represent sources of pro-inflammatory cytokines. Research in animal models has shown that pharmacologic inhibition of IL-23p19 can ameliorate intestinal inflammation. Mirikizumab-mrkz inhibits the release of pro-inflammatory cytokines and chemokines.
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 15, 2025 Supplement 2 · Efficacy LabelLetter
- Jan 15, 2025 Supplement 3 · Efficacy LabelLetter
- Oct 26, 2023 Original approval · Type 1 - New Molecular Entity NovelOrphanLetterLabelReview
2 products under this application
- OMVOH · MIRIKIZUMAB-MRKZ 100MG/ML · INJECTABLE, SUBCUTANEOUS · Prescription
- OMVOH · MIRIKIZUMAB-MRKZ 300MG/15ML · VIAL, SINGLE-USE · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Mirikizumab" as an intervention, any sponsor and status, largest first.
- A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)Pivotal-lookingTerminated
Eli Lilly and CompanyEli Lilly (LLY)
NCT03556202 · 1,936 participants · Start Sep 3, 2018 · Primary completion Feb 7, 2022
Drug: Mirikizumab · For: Psoriasis
Sites: Birmingham, Alabama; Beverly Hills, California; Encinitas, California · 229 sites in all
- A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)Pivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03535194 · 1,484 participants · Start Jun 26, 2018 · Primary completion Mar 5, 2020
Drug: Mirikizumab; Placebo and 1 more · For: Psoriasis
Sites: Birmingham, Alabama; Bakersfield, California; Beverly Hills, California · 178 sites in all
- A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03524092 · 1,328 participants · Start Oct 19, 2018 · Primary completion Nov 3, 2021
Drug: Mirikizumab SC; Mirikizumab IV and 1 more · For: Ulcerative Colitis
Sites: Dothan, Alabama; Litchfield Park, Arizona; Phoenix, Arizona · 385 sites in all
- An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)Pivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03518086 · 1,281 participants · Start Jun 18, 2018 · Primary completion Jan 21, 2021
Drug: Mirikizumab; Placebo · For: Ulcerative Colitis
Sites: Dothan, Alabama; Litchfield Park, Arizona; Phoenix, Arizona · 502 sites in all
- A Study of Mirikizumab (LY3074828) in Participants With Crohn's DiseasePivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03926130 · 1,158 participants · Start Jul 23, 2019 · Primary completion Aug 23, 2023
Drug: Mirikizumab; Mirikizumab and 4 more · For: Crohn's Disease
Sites: Birmingham, Alabama; Dothan, Alabama; Guntersville, Alabama · 580 sites in all
- A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)Pivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT03519945 · 1,058 participants · Start Jul 18, 2018 · Primary completion Mar 4, 2026
Drug: Mirikizumab · For: Ulcerative Colitis
Sites: Dothan, Alabama; Litchfield Park, Arizona; Phoenix, Arizona · 352 sites in all
- A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's DiseasePivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT04232553 · 996 participants · Start Jun 22, 2020 · Primary completion Nov 28, 2024
Drug: Mirikizumab · For: Crohn's Disease
Sites: Dothan, Alabama; Litchfield Park, Arizona; Phoenix, Arizona · 322 sites in all
- A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque PsoriasisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03482011 · 530 participants · Start Apr 24, 2018 · Primary completion Mar 21, 2019
Drug: Mirikizumab; Placebo · For: Psoriasis
Sites: Farmington, Connecticut; Coral Gables, Florida; Ocala, Florida · 69 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- colitis ulcerative155
- injection site pain89
- drug ineffective81
- diarrhoea37
- haematochezia35
- arthralgia30
- incorrect dose administered29
- headache27
- rash27
- frequent bowel movements25
- off label use24
- maternal exposure during pregnancy23
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 22 |
| 2024 | 312 |
| 2025 | 318 |
| 2026 | 251 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Dec 22, 2025
Omvoh, Injection, 100 mg/1 mL (NDC 0002-8011-27). A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-3116-11) will remain.
To Be Discontinued · updated Dec 22, 2025
Omvoh, Injection, 100 mg/1 mL (NDC 0002-8870-27). A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-1442-11) will remain.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Omvoh* (Mirikizumab-Mrkz)
2024 spending
$1.1M
Beneficiaries
42
107 claims
Per beneficiary
$26,594
$1,104.07 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $1,116,928 |
Part B: Omvoh* (Mirikizumab-Mrkz*) · HCPCS J2267
2024 spending
$1.1M
Beneficiaries
54
110 claims
Per beneficiary
$21,213
2024 ASP limit $37.14 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $1,145,487 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G, Dubinsky M, Kobayashi T, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis.
Ananthakrishnan AN, Murad MH, Scott FI, et al. · Gastroenterology 2024 · Systematic Review, Comparative Study
- Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
Ferrante M, D'Haens G, Jairath V, et al. · Lancet 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn's Disease: 2025 AGA Evidence Synthesis.
Singh S, Murad MH, Yuan Y, et al. · Gastroenterology 2025 · Systematic Review, Comparative Study
- Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease.
Sands BE, Peyrin-Biroulet L, Kierkus J, et al. · Gastroenterology 2022 · Clinical Trial, Phase II, Randomized Controlled Trial
- Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
Sandborn WJ, Ferrante M, Bhandari BR, et al. · Gastroenterology 2020 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.